Personal MedSystems GmbH gains international consortium and closes series B financing with a volume of EUR 5 million. Further EUR 0.7 million from existing investors expected.
January 23, 2017
Personal MedSystems GmbH, founded in 2008 by Dr. Markus Riemenschneider and Felix Brand, adds Dutch investor KPN ventures, Sino German High-Tech Fund from Shenzhen/ Hong Kong and Düsseldorf’s NRW.Bank to its existing investor base, which includes French venture capital firm seventure, the KfW banking group and High-Tech Gründerfonds (HTGF). The capital will be used for sales growth and continued innovation on its technology and data platform.
There must be a good reason when Chinese, Dutch, French and German investors join forces to invest into a German start-up. Personal MedSystems, better known under its brand CardioSecur®,offers unique mHealth services and products for people with cardiac symptoms, while at the same time building a smart data platform for predictive values.
CardioSecur® currently offers an instant cardiac monitoring service for private use. It is a smartphone-based, personalized ECG device of the highest clinical-grade quality (15-lead ECG). “CardioSecur is the only technology worldwide that provides instant feedback on heart symptoms when and wherever they occur,” says Dr. Markus Riemenschneider, Managing Director. When logged into the app, the user receives a recommendation on what to do next in less than a minute, and also has the option of sharing the extensive ECG data with his or her personal physician for further use. As only 11% of all infarction patients receive their intervention on time, people with cardiac symptoms need a reliable trigger to act in order to gain certainty.
CardioSecur® gives users peace of mind, minimizes the seriousness of cardiac events and allows effective chronic disease management. Its exceptional ease of use and extensive data allow CardioSecur® to build a smart data pool for predicting critical cardiac events.
“The Series B financing and the strategic leverage points of our new investors will accelerate our market penetration for high-quality cardiac services further and strengthen our pioneering position within mHealth,” says Felix Brand, Managing Director. “Broad availability of CardioSecur’s extensive ECG service makes our smart data platform ever larger day by day, serving as the basis for generating predictive values for serious cardiac events in the future and helping to reduce healthcare costs to society.”
Herman Kienhuis, managing director of KPN Ventures, explains his view on the company: “We see great potential for digital and mobile technologies to improve the quality of healthcare while reducing the cost. Personal MedSystems has developed such an innovation bringing great value to people suffering from heart problems and to cardiologists. In addition to financially supporting its growth, KPN will help Personal MedSystems in bringing CardioSecur® to the Dutch market as well.”
Also new to the investor’s consortium is the Sino-German High-Tech Fund. Its Managing Director Alex Liu states: “We are impressed by the innovative and professional services and products provided by Personal MedSystems GmbH. Its expertise in instant cardiac monitoring service and creative spirits have enabled it to deliver great value in mHealth industry. We look forward to working with the experienced management team to help scale new heights and contribute to public health.”
Seventure’s General Partner Emmanuel Fiessinger, and Kay Balster of HTGF, the early investors since the company’s inception, welcome the new investors: “We are delighted to have completed this substantial financing round with this great consortium of very experienced investors. With the funds of this financing round we are now ready to further demonstrate the benefits of our Cardio Secur instant cardiac monitoring device as the trigger to act.”
About Personal MedSystems GmbH
Personal MedSystems develops and markets products and services for mHealth cardiac care that which are unique in their innovative depth, user friendliness and profound data generating capacity. Its 15-lead ECG sensor services with only for 4 electrodes and a 50 gram light unit linking to a smartphone form the basis for building an unrivaled smart data platform that allows pattern analysis and predictive value generation for critical cardiac events in the future. Personal MedSystems GmbH is a privately owned company.
About KPN Ventures
KPN Ventures is the venturing arm of KPN, The Netherlands’ leading telecom & ICT company. KPN Ventures aims to create value-creating partnership with innovative European technology companies providing access to capital, expertise, network and customer channels. It focuses early growth-stage investments in European technology companies in the segments: Internet of Things, Connected Home, Digital Health, Cyber Security, Mobile/OTT services, Cloud Computing and Data & Analytics. KPN Ventures has its main office in Rotterdam, The Netherlands and has invested in a.o. Actility, EclecticIQ, SecurityMatters and Viloc.
About Sino-German High-Tech Fund
Sino-German High-Tech Fund (“SGHF”) is founded in 2016 focusing on investment in growing enterprises of Industry 4.0, IOT industry, Healthcare, Life Science and other high-tech industries in EU especially in Germany. SGHF is strongly supported by Chinese and German government and has a strategic partnership with listed companies in related industries, state-backed investment funds and financial groups.
Sino-German High-Tech Fund
Three Pacific Plaza
No.1 Queen’s Road East
Wan Chai Hong Kong
Phone: +86 138-1782-9482
NRW.BANK is the development bank for North Rhine-Westphalia. It essentially orients its equity products on the life cycle of the firms. Thus, the regional NRW.BANK.Seed Fund and the NRW.BANK.Kreativwirtschaftsfonds invigorate the early-phase funding in North Rhine Westphalia. Young high-tech firms are supported by funding of up to € 8 million via the NRW.BANK.Venture Fund. For businesses with above-average growth prospects and a convincing management team NRW.BANK provides contacts to potential private investors within the win NRW.BANK Business Angels Initiative. In addition, the NRW.BANK.Mittelstandsfonds and the NRW.BANK.Spezialfonds provide equity in the amount of € 1 to 7 million to growth intensive mid-cap companies in special funding and restructuring situations.
Tel.: +49 211 91741-1847
Mobil: +49 151 15179261
About Seventure Partners
With over €600m in assets under management as of the end of 2016, Seventure Partners is a leading venture capital firm in Europe. Since 1997, Seventure Partners has invested in innovative businesses with high growth potential in digital technologies, in France and Germany, and in the life sciences field across Europe and North America. In life sciences, the four areas of focus include biotechnology and pharmaceuticals, connected health and medtech, industrial biotechnology, and last but not least: the MICROBIOME, nutrition, foodtech and personalized medicine. Investments can range between €500k and €10m per round, or up to €20m per company, from early to late stage. In December 2013, Seventure Partners successfully launched Health for Life Capital™ which has attracted strategic investments from prestigious organizations including Danone, Tereos, Tornier, Lesaffre, Bel and Novartis as well as entrepreneurs and financial institutions.
Seventure is a subsidiary of Natixis Global Asset Management. Natixis is the corporate investment management and financial services arm of Groupe BPCE, the second-largest French bank.
For more details: www.seventure.com
About High-Tech Gründerfonds
High-Tech Gründerfonds invests in young, high potential high-tech start-ups. The seed financing provided is designed to enable start-ups to take an idea through prototyping and to market launch. Typically, High-Tech Gründerfonds invests EUR 600,000 in the seed stage, with the potential for up to a total of EUR 2 million per portfolio company in follow-on financing. Investors in this public/private partnership include the Federal Ministry of Economics and Energy, the KfW Banking Group, as well as strategic corporate investors including ALTANA, BASF, Bayer, B. Braun, Robert Bosch, CEWE, Daimler, Deutsche Post DHL, Deutsche Telekom, Evonik, Innogy, Lanxess, media + more venture Beteiligungs GmbH & Co. KG, METRO, Qiagen, SAP, Tengelmann and Carl Zeiss. High-Tech Gründerfonds has about EUR 576 million under management in two funds (EUR 272 million HTGF I, EUR 304 million HTGF II).